<DOC>
	<DOCNO>NCT02330081</DOCNO>
	<brief_summary>A total twelve healthy volunteer donate one unit fresh whole blood . This unit treat Mirasol Pathogen Reduction Technology Whole blood store 24h . At end storage , platelet concentrate separate unit , test key vitro parameter radiolabeled . On day ( 24h donation whole blood ) , volunteer donate fresh sample whole blood . Platelets separate fresh sample label another radio-isotope . Then , two radiolabeled platelet aliquot infuse simultaneously recovery survival two type platelet measure .</brief_summary>
	<brief_title>Survival Recovery Radio-labeled Platelets Derived From Mirasol-treated Whole Blood</brief_title>
	<detailed_description>The study prospective , single-center , single-arm , intra-subject control , open-label design . Subjects donate one unit fresh whole blood . This unit treat Mirasol PRT System whole blood store 24 hour ± 1 hour 22 ± 2°C . At end storage , platelet concentrate separate unit accord Biomedical Excellence Safer Transfusion ( BEST ) procedures . An aliquot remove platelet concentrate test radiolabeling reinfusion . The platelet Mirasol-treated whole blood test key vitro parameter directly treatment ( Day 0 ) end storage ( Day 1 ) . Sterility test also conduct store unit . An aliquot platelet concentrate separate unit store Mirasol-treated whole blood radiolabeled either 111Indium Oxine 51Chromium , autologously infuse . An intra-subject control utilized per BEST guideline platelet radiolabeling procedure . On day infusion , subject donate fresh sample whole blood . Platelets separate fresh sample label radio-isotope use label subject 's Mirasol-treated platelet sample . The two radiolabeled platelet aliquot ( Mirasol-treated fresh control ) infuse simultaneously , recovery survival two type platelet measure accord standard institutional practice .</detailed_description>
	<criteria>1 . Healthy adult subject , meet inclusion criterion define Blood Center whole blood donation . 2 . Age ≥ 18 &lt; 70 year 3 . Able commit study followup schedule . 4 . Subjects must adequate antecubital venous access whole blood collection followup blood draw . 5 . Subjects childbearing potential ( female male ) must agree use effective contraception per site guideline abstain heterosexual intercourse course study . 6 . Female childbearing potential must willing take pregnancy test prior infusion radiolabeled platelet . 7 . Subjects must agree report adverse event ( AEs ) require reporting period . 1 . Use medication interfere platelet function within 48 hour plan whole blood collection . 2 . Participation currently , within last 12 month , another investigational trial would potentially interfere analysis investigation ( e.g. , pharmaceutical ) . 3 . Inability comply protocol opinion investigator . 4 . Unable unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>pathogen reduction technology</keyword>
	<keyword>whole blood</keyword>
	<keyword>Platelets</keyword>
	<keyword>Mirasol</keyword>
</DOC>